Compare Eli Lilly And Co (LLY) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Nomura Holdings Inc — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Nomura Holdings Inc trades at $9.61 (market cap $27.55B). The key difference: Eli Lilly And Co is far larger — about 37.7× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.4%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Nomura Holdings Inc for 55 Days on average.
| LLY | NMR | |
|---|---|---|
Market Cap | $1.04T | $27.55B |
Volume | 3,064,878 | 782,470 |
Sector | Health | Financials |
52-Week High | $1.28K | $10.86 |
52-Week Low | $799.57 | $6.73 |
Typical Hold Time | 93 Days | 55 Days |
Enterprise Value | $1.09T | $38.54T |
Dividend Yield | 0.59% | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Nomura Holdings (NMR) trades at $9.59, up 0.63% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with revenue growth from $1.66T to $1.98T projected for 2026, net income margin of 20.4%, and attractive valuation ratios including P/E of 11.33. Recent news highlights technical pattern recognition and inclusion on Zacks Strong Buy lists, though cash flow trends show operational challenges.
NMR presents a mixed outlook with undervalued fundamentals against bearish technicals. Investment opportunity lies in discounted valuation and earnings momentum, but risks include negative operating cash flows, rising debt-to-asset ratios, and inconsistent earnings performance. Analyst consensus leans cautious with 67% hold ratings despite recent positive coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
